New interaction modalities between the pharmaceutical industry and physicians.

Area of Science:

• Medical Ethics
• Pharmaceutical Marketing
• Physician-Industry Relations

Background:

• COVID-19 pandemic restrictions altered traditional pharmaceutical industry and physician interactions.
• A shift towards unilateral drug promotion via academic events featuring invited "experts" has emerged.
• These events may prioritize commercial interests over evidence-based, patient-centered disease management.

Purpose of the Study:

• To analyze the ethical implications of new pharmaceutical promotion strategies.
• To evaluate the impact of industry-sponsored academic events on medical practice.
• To propose considerations for the medical community regarding physician-industry relationships.

Main Methods:

• Analysis of recent trends in pharmaceutical promotion.
• Ethical review of industry-sponsored academic events.
• Formulation of recommendations by a National Academy of Medicine committee.

Main Results:

• Pharmaceutical promotion has shifted to academic events with "expert" speakers.
• These events may exhibit bias towards specific drugs, potentially neglecting alternatives.
• The focus may shift from optimal disease care to commercial drug promotion.

Conclusions:

• Physician-industry interactions require ethical scrutiny, especially post-pandemic.
• Transparency and a focus on patient well-being are crucial in academic medical settings.
• Recommendations are provided to guide physicians in navigating these evolving promotional landscapes.